Health · Medical Research · 2 hrs ago
Trials Find ALP Normalization With Two PBC Drugs
New trial findings support two drugs for primary biliary cholangitis, or PBC.
The drugs are elafibranor, sold as Iqirvo, and seladelpar, sold as Livdelzi.
The findings concern patients with PBC who had elevated alkaline phosphatase (ALP) levels.
Both drugs led to ALP levels returning to normal in most patients in this group.
The results add trial evidence for drugs that were approved quickly, according to the report's headline.
The available information does not say what happens next or give further details about the trials.
Trials found that elafibranor and seladelpar led to alkaline phosphatase normalization in the vast majority of patients described.
The patients had primary biliary cholangitis and elevated alkaline phosphatase levels.
The article says the patients had elevated levels after an incomplete... but the available text ends before completing that detail.
The report was published by MedPage Today on November 6, 2026.
- Who
- Patients with primary biliary cholangitis who had elevated alkaline phosphatase levels.
- What
- Treatment with elafibranor and seladelpar led to alkaline phosphatase normalization in the vast majority of patients described.
- When
- November 6, 2026, the publication date.
- Where
- Not stated.
- Why
- Not stated.
This story does not have two clearly opposing sides.
This story does not have a timeline yet.
- Drugs
- Elafibranor (Iqirvo) and seladelpar (Livdelzi)
- Condition
- Primary biliary cholangitis (PBC)
- Outcome
- ALP normalization in the vast majority of patients described
- Publication date
- November 6, 2026
What people are saying
Treatment with both elafibranor (Iqirvo) and seladelpar (Livdelzi) led to alkaline phosphatase (ALP) normalization in the vast majority of patients with primary biliary cholangitis (PBC) who had elevated ALP levels after an incomplete